中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

38 records (took 0.022 seconds)

    CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION
    21.
    发明申请
    CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION 有权

    公开(公告)号：US20210267977A1

    公开(公告)日：2021-09-02

    申请号：US17156233

    申请日：2021-01-22

    Applicant: Universitätsspital Basel

    Inventor： Matthias Emanuel LIECHTI

    IPC: A61K31/517 ,  A61K31/48 ,  A61P25/26

    Abstract: A composition for treating an individual while reducing acute effects, including effective amounts of a psychedelic drug and a duration shortening agent. A method of treating an individual with a psychedelic drug and reducing its acute duration of action, by administering a psychedelic drug to the individual, administering a duration shortening agent to the individual, and shortening and/or reducing the acute effects of the psychedelic drug. A method of stopping the acute duration of action of a psychedelic drug in an individual, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug and stopping the acute effects of the psychedelic drug.

    Assessment of the lung parenchyma by means of magnetic resonance images
    23.
    发明授权
    Assessment of the lung parenchyma by means of magnetic resonance images 有权

    公开(公告)号：US10517509B2

    公开(公告)日：2019-12-31

    申请号：US15251285

    申请日：2016-08-30

    Applicant: UNIVERSITÄTSSPITAL BASEL

    Inventor： Oliver Bieri ,  Orso Andrea Pusterla ,  Grzegorz Bauman

    IPC: A61B5/055 ,  A61B5/091 ,  G01R33/56

    Abstract: A method for the assessment of the lung parenchyma in a human or an animal is indicated using a series of magnetic resonance (MR) images of the lung parenchyma acquired at different breathing positions in the same human or animal. The method comprises at least the steps of a.) estimating a change of the lung volume VL between the different breathing positions, b.) determining a signal intensity SI({right arrow over (x)}i) in at least one same region or position {right arrow over (x)}i of the lung parenchyma for each of the MR images, and c.) determining at least one respiratory index α({right arrow over (x)}i) according to the formula α ⁡ ( x → i ) = - d ⁡ ( log ⁡ ( SI ⁡ ( x → i ) ) ) d ⁡ ( log ⁡ ( V L ) ) . ( Fig . ⁢ 2 )

    ASSESSMENT OF THE LUNG PARENCHYMA BY MEANS OF MAGNETIC RESONANCE IMAGES
    24.
    发明申请
    ASSESSMENT OF THE LUNG PARENCHYMA BY MEANS OF MAGNETIC RESONANCE IMAGES 审中-公开

    公开(公告)号：US20180055414A1

    公开(公告)日：2018-03-01

    申请号：US15251285

    申请日：2016-08-30

    Applicant: UNIVERSITÄTSSPITAL BASEL

    Inventor： Oliver BIERI ,  Orso Andrea PUSTERLA ,  Grzegorz BAUMAN

    IPC: A61B5/091 ,  A61B5/055

    CPC classification number: A61B5/091 ,  A61B5/055 ,  G01R33/4816 ,  G01R33/5608 ,  G01R33/5614

    Abstract: A method for the assessment of the lung parenchyma in a human or an animal is indicated using a series of magnetic resonance (MR) images of the lung parenchyma acquired at different breathing positions in the same human or animal. The method comprises at least the steps of a.) estimating a change of the lung volume VL between the different breathing positions, b.) determining a signal intensity SI({right arrow over (x)}i) in at least one same region or position {right arrow over (x)}i of the lung parenchyma for each of the MR images, and c.) determining at least one respiratory index α({right arrow over (x)}i) according to the formula α  ( x → i ) = - d  ( log  ( SI  ( x → i ) ) ) d  ( log  ( V L ) ) . ( Fig .  2 )

    METHOD FOR THE SIMULTANEOUS AMPLIFICATION OF A PLURALITY OF DIFFERENT NUCLEIC ACID TARGET SEQUENCES
    26.
    发明申请
    METHOD FOR THE SIMULTANEOUS AMPLIFICATION OF A PLURALITY OF DIFFERENT NUCLEIC ACID TARGET SEQUENCES 审中-公开
    同时扩增不同核酸酸性目标序列的方法

    公开(公告)号：US20150267256A1

    公开(公告)日：2015-09-24

    申请号：US14438074

    申请日：2013-10-30

    Applicant: UNIVERSITÄTSSPITAL BASEL

    Inventor： Jochen Kinter ,  Michael Sinnreich

    IPC: C12Q1/68

    CPC classification number: C12Q1/6883 ,  C12Q1/6858 ,  C12Q1/6888 ,  C12Q2600/16 ,  C12Q2525/204 ,  C12Q2537/143 ,  C12Q2549/119

    Abstract: The present invention relates to a method for the simultaneous amplification of a plurality of different nucleic acid target sequences comprising the steps of providing a plurality of different nucleic acid polymers as templates, each template comprising a specific target sequence and a primer annealing sequence located downstream of the target sequence, and amplifying the template by a polymerase dependent amplification reaction using a primer oligonucleotide comprising a primer sequence which is at least essentially complementary to the primer annealing sequence. The method is characterized in that for the polymerase dependent amplification reaction a set of primer oligonucleotides is used, said set comprising at least two primer oligonucleotides which are able to anneal to the primer annealing sequence of the same template and which differ from each other in the efficiency for the polymerase dependent amplification reaction to take place.

    Abstract translation: 本发明涉及同时扩增多个不同核酸靶序列的方法，包括以下步骤：提供多种不同的核酸聚合物作为模板，每个模板包含特定的靶序列和位于 靶序列，并使用包含与引物退火序列至少基本上互补的引物序列的引物寡核苷酸，通过聚合酶依赖性扩增反应扩增模板。 该方法的特征在于，对于聚合酶依赖性扩增反应，使用一组引物寡核苷酸，所述组包含至少两个引物寡核苷酸，其能够退火到相同模板的引物退火序列，并且在 聚合酶依赖性扩增反应发生的效率。

    LSD dose identification
    27.
    发明授权
    LSD dose identification 有权

    公开(公告)号：US11717517B2

    公开(公告)日：2023-08-08

    申请号：US17225715

    申请日：2021-04-08

    Applicant: Universitätsspital Basel

    Inventor： Matthias Emanuel Liechti ,  Friederike Sophie Holze

    IPC: A61K31/48 ,  A61K31/4045 ,  A61K31/675 ,  A61P25/24 ,  G01N33/68 ,  A61K31/137

    CPC classification number: A61K31/48 ,  A61K31/137 ,  A61K31/4045 ,  A61K31/675 ,  A61P25/24 ,  G01N33/6893 ,  G01N2800/304 ,  G01N2800/52

    Abstract: A method of dosing and treating patients with a psychedelic, by administering a psychedelic at a dose of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, and producing maximum positive subjective acute effects that are known to be associated with more positive long-term outcomes and minimizing negative acute effects. A method of determining a dose of a psychedelic for an individual, by administering a dose of a psychedelic to the individual of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual. Methods of treating psychiatric conditions or providing therapy. A method of defining therapeutic doses of a psychedelic in clinical trials. A method of monitoring individuals for depression after treatment with LSD.

    COMBINATION PRODUCT USING 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND CARVEDILOL FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
    28.
    发明申请
    COMBINATION PRODUCT USING 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND CARVEDILOL FOR THE TREATMENT OF PSYCHIATRIC DISORDERS 有权

    公开(公告)号：US20220323405A1

    公开(公告)日：2022-10-13

    申请号：US17692094

    申请日：2022-03-10

    Applicant: Universitätsspital Basel

    Inventor： Matthias Emanuel LIECHTI

    IPC: A61K31/36 ,  A61P9/12 ,  A61K31/403

    Abstract: A composition for treating an individual while reducing acute adverse effects of an empathogen/entactogen, including effective amounts of the empathogen/entactogen and an adverse effect-reducing agent that blocks adverse effects of the empathogen/entactogen. A method of treating an individual with an empathogen/entactogen and reducing its acute adverse effects, by administering an empathogen/entactogen to the individual, administering an adverse effect-reducing agent to the individual, and reducing the acute adverse effects of the empathogen/entactogen. A method of stopping the acute cardiostimulant and hyperthermic action of an empathogen/entactogen in an individual, by administering an adverse effect-reducing agent to the individual after the individual has taken the empathogen/entactogen and stopping the acute adverse effects of the empathogen/entactogen. A method of treating an individual at risk of cardiovascular events and/or hyperthermia with an empathogen/entactogen.

    Devices and Methods for Determining Heart Function of a Living Subject
    29.
    发明申请
    Devices and Methods for Determining Heart Function of a Living Subject 有权

    公开(公告)号：US20220296875A1

    公开(公告)日：2022-09-22

    申请号：US17835132

    申请日：2022-06-08

    Applicant: HIGHDIM GMBH ,  Universitätsspital Basel

    Inventor： Oleksii Morozov ,  Patrick Hunziker

    IPC: A61M60/50 ,  A61B5/00 ,  A61B5/01 ,  A61B5/0205 ,  A61B5/029 ,  A61B5/05 ,  A61B8/06 ,  A61M60/135 ,  A61M60/871

    Abstract: The present invention relates to systems, methods and algorithms for determination of heart pump function and their use in livings subject are described.
    The invention further relates to complementary parts of such systems that work best in combination.
    Medical catheters, sheaths and shafts are disclosed that carry an arrangement of integrated digital sensor systems-on-chip (SoC) in the portion thereof residing inside the body. These devices combine at their portion that resides inside the body, the complete chain of signal transduction, signal analog-to-digital conversion and digital signal transmission, and allow to acquire single and multiple physical entities in a single setup. In specific instances the devices integrate wireless data transfer functionality, and in specific instances they integrate wireless energy harvesting for battery-free functionality.
    The present invention further describes complementary monitor systems that are suited for reception, processing and analysis of data acquired by such catheters/sheaths/shafts to yield a robust assessment of cardiac performance.
    Moreover, the present invention relates to innovations which render such systems applicable to patients with and without cardiac assist devices.

Patent Agency Ranking